Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Paul Wang, M.D.
Seaside Therapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
28 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Southwest Autism Research & Resource Center
Phoenix, Arizona, United States
- Miller Children'S Hospital
Long Beach, California, United States
- University of California-Davis, M.I.N.D. Institute
Sacramento, California, United States
- Psychiatric Centers at San Diego
San Diego, California, United States
- University of Colorado Denver, Children'S Hospital
Aurora, Colorado, United States
- University of Miami, Mailman Center for Child Development
Miami, Florida, United States
- Lake Mary Pediatrics
Orange City, Florida, United States
- Emory University School of Medicine
Decatur, Georgia, United States
- Rush University Medical Center
Chicago, Illinois, United States
- Kansas University Clinical Research Center
Fairway, Kansas, United States
- Kennedy Krieger Institute
Baltimore, Maryland, United States
- University of Massachusetts
Worcester, Massachusetts, United States
- Children'S Hospital of Michigan
Detriot, Michigan, United States
- University of Missouri, Thompson Research Center for Autism & Neurodevelopmental Disorders
Columbia, Missouri, United States
- Seaver Autism Center, Mount Sinai Medical Center
New York, New York, United States
- New York State Institute for Basic Research in Developmental Disabilities
Staten Island, New York, United States
- Duke Clinical Research Unit
Durham, North Carolina, United States
- Akron Children'S Hospital
Akron, Ohio, United States
- Cincinnati Children'S Hospital
Cincinnati, Ohio, United States
- University of Oklahoma, Physician'S Child Study Center
Oklahoma City, Oklahoma, United States
- Suburban Research Associates/elwyn Genetics
Media, Pennsylvania, United States
- Greenwood Genetics Center
Greenwood, South Carolina, United States
- Vanderbilt Kennedy Center
Nashville, Tennessee, United States
- Childrens Medical Center Dallas
Dallas, Texas, United States
- Red Oaks Psychiatry Associates, P.A.
Houston, Texas, United States
- Texas Children'S Hospital
Houston, Texas, United States
- Road Runner Research
San Antonio, Texas, United States
- Seattle Children'S Hospital
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2011
- Primary completion
- 30 Jun 2013
- Completion
- —
- Last update posted
- 31 Jul 2013
- Registered enrollment
- 172
- Registry id
- NCT01325220
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.